EGFR and non-small cell lung carcinoma: Moreover, in patients with metastatic NSCLC, ctDNA has been approved as a non-invasive alternative to tumor biopsy samples to facilitate the detection of EGFR (epidermal growth factor receptor)-activating mutations (134).